Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease — Stella

Home/Pulmonary Fibrosis, Interstitial Lung Disease/

View on ClinicalTrials.gov

Recruiting

Back to Pulmonary Fibrosis, Interstitial Lung Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Denmark

Aarhus University Hospital, Aarhus N

Odense University Hospital, Odense C

Estonia

Tartu University Hospital,, Tartu

Key details

Phase

Safety & dosing

Sponsor

Vejle Hospital

Collaborators

Odense Patient Data Explorative Network

Enrollment target

~140 participants

Started

August 2025

Primary completion

December 2028

Age range

18 Years and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.